$3.09
0.64%
Nasdaq, Fri, Sep 25 2026.
ISIN
US79400X1072
Symbol
SLRX

Salarius Pharmaceuticals Inc Stock price

$3.09
+0.11 3.69% 1M
-4.26 57.96% 6M
-4.70 60.31% YTD
-44.31 93.48% 1Y
-1,033.71 99.70% 3Y
-39,236.91 99.99% 5Y
-10,079,996.91 100.00% 10Y
-13,454,996.91 100.00% 20Y
Nasdaq, Closing price Fri, Sep 25 2026
-0.02 0.64%
ISIN
US79400X1072
Symbol
SLRX
Industry

Is Salarius Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.

Key metrics

Basic
Market capitalization
-
Enterprise Value
-
Net debt
positive
Cash
$4.8m
Shares outstanding
940.0k
Valuation (TTM | estimate)
P/E
negative
P/S
- | -
EV/Sales
- | -
EV/FCF
-
P/B
-
Financial Health
Equity Ratio
50.0%
Return on Equity
-368.8%
ROCE
-119.3%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-5.1m
EBIT
$-5.1m
Net Income
$-5.0m
Free Cash Flow
$-4.4m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
2.9%
EBIT
2.8%
Net Income
-0.2%
Free Cash Flow
16.3%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow
-
More
EPS
$-10.4
FCF per Share
$-4.7
Short interest
3.2%
Employees
2
Rev per Employee
$0.0

Salarius Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Salarius Pharmaceuticals Inc forecast:

3x Hold
50%
3x Sell
50%

Analyst Opinions

6 Analysts have issued a Salarius Pharmaceuticals Inc forecast:

Hold
50%
Sell
50%

Financial data from Salarius Pharmaceuticals Inc

Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 4.64 4.64
2% 2%
-
- Research and Development Expense 0.43 0.43
34% 34%
-
-5.06 -5.06
3% 3%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -5.07 -5.07
3% 3%
-
Net Profit -5 -5
0% 0%
-

In millions USD.

Don't miss a Thing! We will send you all news about Salarius Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company. The firm focuses on the development of Salarius' clinical pipeline, which targets rare, orphan cancers and cancers with a high unmet need. The company was founded in 2014 and is headquartered in Houston, TX.

Head office United States
CEO Mr. Rosenblum
Employees 2
Founded 2014
Website salariuspharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today